30
CARDIOVASCULAR
hamburger

Unparalleled Safety with XIENCE™ Stent1

XIENCE™ Stent's Excellent Outcomes in Complex Patients2-4

Early outcomes with XIENCE™ Stent, implanted in complex patients, reveal excellent rates of definite stent thrombosis (ST) at 30 days:

  • Bifurcations Lesions: 0.0%2
  • Calcified Lesions: 0.0%3
  • Long Lesions: 0.3% ST4


Lower Early Stent Thrombosis Rates with XIENCE™ Stent vs Other DES

XIENCE™ Stent Acute ST Rate 75% Lower vs Other DES

With XIENCE™ Stent there is a 75% lower rate of acute (24-hour) definite ST compared to Synergy.5

Acute definite ST is 75% lower with XIENCE Stent vs Synergy: 0.3% with XIENCE Stent and 1.2% with Synergy.


XIENCE™ Stent Early ST Rate 88% Lower vs Other DES

With XIENCE™ Stent there is an 88% lower rate of early (30-day) definite ST compared to Resolute.6

Early definite ST is 88% lower with XIENCE Stent vs Resolute: 0.1% with XIENCE Stent and 0.8% with Resolute.

Consistently Lowest Rates of Late and Very Late Stent Thrombosis

XIENCE™ Stent has the most exceptional rates—and consistently the lowest rates—of late and very late ST.1 It’s another example of how XIENCE™ Stent delivers unparalleled patient outcomes which last far beyond the intervention.1

 

Even when examining ultra-long-term safety, XIENCE™ Stent reveals excellent patient outcomes—0.8% ST 10 years after PCI.12

At 10 years, XIENCE Stent has revealed 0.8% stent thrombosis rates.

  • Manuals & Technical Resources
  • Cardiovascular Products
  • Customer Service

References

  1. Zanchin C, et al. JACC Cardiovasc Interv. 2019;12(17):1665-1675. Serruys P, et al. N Engl J Med. 2010;363:136-146. Shiomi H, et al. JACC Cardiovasc Interv. 2019;12:637-647. Kufner S, et al. Circulation. 2019:139(3):325-333. Palmerini T, et al. Lancet. 2013;379:1393-1402. Bangalore S, et al. Circulation. 2012;125:2873-2891. Bangalore S, et al. Circ Cardiovasc Interv. 2013;6(6):378-390. Pilgrim T, et al. Lancet. 2014;384:2111-2122. Pilgrim T, et al. Lancet. 2018;392:737-746. Data on file at Abbott.
  2. Džavík V, et al. Catheter Cardiovasc Interv. 2013;82(3):E163-E172.
  3. Onuma Y, et al. Catheter Cardiovasc Interv. 2010;76:634-642.
  4. Hong S, et al. JACC Cardiovasc Interv. 2016;9:1438-1446.
  5. Zanchin C, et al. JACC Cardiovasc Interv. 2019;12(17):1665-1675.
  6. Serruys P, et al. N Engl J Med. 2010;363:136-146.
  7. von Birgelen C, et al. J Am Coll Cardiol. 2012;59:1350-1361.
  8. Natsuaki M, et al. Cardiovasc Interv Ther. 2016 31(3):196-209.
  9. van Geuns RJ, et al. TCT 2019. IDEAL-LM.
  10. Chevalier B, et al. EuroIntervention. 2018;13:1561-1564.
  11. Gao R, et al. TCT 2019. ABSORB China.
  12. Kufner S, et al. Circulation. 2019:139(3):325-333.

MAT-2101793 v1.0

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.

False
accessibility
© 2016 Abbott. All Rights Reserved. Please read the Legal Notice for further details.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

accessibility

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.